Consumer News Experimental Drug Helped Alzheimer S Patients In Small Trial

Can GLP-1 drugs treat Alzheimer’s? Novo Nordisk will soon announce key results

Novo Nordisk will soon announce the results of perhaps the most ambitious studies yet of its GLP-1 drug: whether it can help slow Alzheimer's. Read More

Pharmalittle: We’re reading about a Novo drug and Alzheimer’s, a Sarepta drug warning, and more

Novo Nordisk is expected to announce soon whether its blockbuster GLP-1 drug semaglutide can help slow Alzheimer’s disease ... Read More

Novo Nordisk Will Soon Reveal Whether Its GLP-1 Drug Can Slow Alzheimer's

Novo's upcoming Alzheimer's trial results will test whether Rybelsus can slow cognitive decline and reshape treatment expectations for GLP-1 drugs. Read More

Alzheimer’s pill could reduce brain decline in some high-risk patients, trial suggests

An experimental pill could slow memory loss and brain shrinkage in some Alzheimer’s patients, new research suggests. The pill, called ALZ-801 (valiltramiprosate), was shown to be effective in people ... Read More

Oligomerix Awarded $0.5 M phase I NIH SBIR Fast-Track Grant to Conduct Safety Studies that will Support Clinical Studies of OLX-07010 for Alzheimer's Patients

Company gains NIH Fast-Track award supporting long-term dosing in Alzheimer's patients for planned Phase 1b studies to evaluate OLX-07010, a small molecule inhibitor of tau protein self-association-- ... Read More

High-stakes Novo Nordisk Alzheimer's studies could yield answers on GLP-1 benefit

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can slow ... Read More

The surprising drugs that could be used to halt Alzheimer’s

Study found drugs used to prevent shingles and treat erectile dysfunction could be promising for Alzheimer’s patients ... Read More